Size of hippocampal pyramidal neurons in schizophrenia

J. R. HIGHLEY, M. A. WALKER, B. McDONALD, T. J. CROW and M. M. ESIRI

Background Meta-analyses of hippocampal size have indicated that this structure is smaller in schizophrenia. This could reflect a reduction in the size of constituent neurons or a reduced number of neurons.

Aims To measure the size of hippocampal pyramidal neurons in the brains of people with and without schizophrenia.

Method Pyramidal neuron size in hippocampal subfields was estimated stereologically from sections taken at 5 mm intervals throughout the whole length of right and left hippocampi from the brains of 13 people with schizophrenia and 16 controls. Results were assessed using repeated-measures analysis of covariance looking for a main effect of diagnosis and gender, and interactions of these with side.

Results We were unable to detect significant differences related to diagnosis, gender or side for any hippocampal subfield for this series of cases.

Conclusions For this series of brains, hippocampal cell size is unchanged in schizophrenia.

Declaration of interest None. Funding detailed in Acknowledgements.

The hippocampus has interested investigators into schizophrenia for many decades. Experimental and human studies have shown its undoubted importance for memory function, which is selectively impaired in people with schizophrenia (Gruzelier et al, 1988; Saykin et al, 1991; Gur et al, 1998). Furthermore, some structural imaging studies of living patients, as well as post-mortem studies, report reductions in hippocampal size in schizophrenia (Bogerts et al, 1985; Farkai & Bogerts, 1986; Jeste & Lohr, 1989; Nelson et al, 1998) – although not all studies confirm this, perhaps because the numbers of individuals studied were sometimes too low to detect the quite subtle reductions described (Altshuler et al, 1990; Bruton et al, 1990; Heckers et al, 1990, 1991). The meta-analysis of in vivo magnetic resonance imaging (MRI) studies by Nelson et al (1998) indicated a reduction in hippocampal size of approximately 4%.

Reduction in size of a brain structure may reflect a reduced size of the constituent glial cells and neurons and their processes as well as (or as an alternative to) a reduced number of neurons. Thus, it is important to document estimates of cell size as well as cell number in brain structures that are of interest in schizophrenia. Here we present our findings with respect to pyramidal cell volume, estimated stereologically, in the hippocampus on both sides of brains taken from 13 people with schizophrenia and 16 controls.

METHOD

The brains studied in this investigation were a subset of 29 samples from a collection that has been described elsewhere (Highley et al, 1999; McDonald et al, 2000; Walker et al, 2002). In brief, brains were collected post mortem from patients with schizophrenia and a control group, and fixed by suspension in 10% formalin solution. The case notes of the patients and controls were assessed by a psychiatrist (T.J.C. or Dr Stephen J. Cooper from Queen’s University, Belfast) to ensure that they either fulfilled DSM-IV criteria for schizophrenia or schizoaffective disorder (American Psychiatric Association, 1994), or were free of psychopathological disorder. The next of kin gave consent for use of brain tissue for research. All brains were examined by a neuropathologist (B.M.), masked to diagnosis and gender, who confirmed them as being free from significant neuropathological changes. In particular, there was no evidence of cerebrovascular disease, Alzheimer’s disease or Parkinson’s disease. All measures were made (by M.A.W.) masked to diagnosis and gender. The demographic details of the brain donors in this study are given in Table 1.

The temporal lobes were dissected away from the rest of the brain, and sliced into 5 mm coronal slices throughout their entire length, such that the entirety of the hippocampus was available for histological examination. Each slice was embedded in paraffin wax, and a 25 μm section was cut from its anterior face, mounted on a coated slide, stained with cresyl violet and luxol fast blue, and coverslipped.

The outlines of four cytoarchitecturally defined hippocampal subfields were delineated in the manner described by West & Gundersen (1990):

(a) the hilus (CA4)
(b) an amalgamation of the CA2 and CA3 subfields (hereafter CA2/3)
(c) the CA1 subfield
d) the subiculum.

The volume density ($V_o$) of these subfields was measured on both sides of the brain, using stereological point-counting techniques (Howard & Reed, 1998). Volume density in this study refers to the proportion of each hippocampal subfield that is occupied by pyramidal neuronal cell bodies.

The prepared slides were examined using a ×60 objective and an Olympus BX50 microscope mounted with a JVC TK-C1380 colour video camera and stage motor, which in turn were controlled and viewed on a computer running the Olympus Cast-Grid 2.0 stereology sampling software. On each slide, each subfield was examined at specific points positioned in a raster search pattern array which covered...
In the entirety of the subfield (Fig. 1). The search pattern was 0.5 × 0.5 mm² for the hilus and CA2/3 subfields, 1 × 1 mm² for the CA1 subfield, and 0.75 × 0.75 mm² for the subiculum. Each subfield appeared on an average of 6.7 slides per case (range 3–15; in a few cases the hippocampus was cut obliquely, which meant it appeared in few sections, although this did not alter the intensity of the sampling). Neuron density (Nv) was counted in a mean 89 frames per case; a mean of 89 neurons were counted for Vv estimation per case. At each such point a plane within the section was brought into focus, and an array of 36 random test points thrown over the microscope image. The number of test points that fell over pyramidal cell bodies was counted, and the mean number of point counts (P) per image calculated. Pyramidal cells were identified on the basis of their position, orientation shape, presence of an apical dendrite and prominent, single nucleolus. The volume density was calculated for each subfield by

\[ \text{Vv} = \frac{P}{36}. \]

In a previous study, the neuron density (number of cells per unit volume, Nv) within each hippocampal subfield had been estimated (Walker et al., 2002; further details available from the author upon request). Using these data, the mean pyramidal cell body volume (Vv) was calculated using the formula

\[ \text{Vv} = \frac{\text{Nv}}{Nv}. \]

**Statistical methods**

The cell volume for each subfield was assessed by repeated-measures analysis of covariance (ANCOVA), with diagnosis and gender as between-subject factors and side as a within-subject factor, using SAS version 6.12 for Macintosh. As there was a significant difference between the brains from the control and schizophrenia groups in the duration spent in formalin prior to histological preparation, this variable was entered as a covariate in the ANCOVA model. The main effect of diagnosis, gender, and interactions of these with side, gender, and gender and side together were tested for. Given the number of effects tested for each measure, α was set at 0.01. Thus, for an effect to be significant, it had to generate a value for P of 0.01 or below.

**RESULTS**

**Quality of measures**

The observed coefficient of error (OCE) for the individual estimates of subfield volume, cell density and cell number were calculated for 10 cases in the manner described by Gundersen & Jensen (1987) and West & Gundersen (1990). This coefficient is a measure of the variability of measures of a specific structure across different slices; possible values are 0 to 1. It is increased by irregularly shaped structures and by inaccurate and unreliable measurement. For the measures of Vv, the mean OCE values were all ≤0.121. For the measures of Vv, mean OCE values were all ≤0.061. For Nv, the mean values of OCE were all ≤0.1001. The values of

**Table 1** Preparation and donor characteristics of the brain samples used in this study

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th></th>
<th>Schizophrenia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td></td>
<td>(n=7)</td>
<td>(n=9)</td>
<td>(n=5)</td>
<td>(n=8)</td>
</tr>
<tr>
<td>Age (years):² mean (s.d.)</td>
<td>62.71 (9.88)</td>
<td>58.78 (12.01)</td>
<td>61.20 (13.95)</td>
<td>62.75 (10.00)</td>
</tr>
<tr>
<td>Death to post-mortem interval (h):² mean (s.d.)</td>
<td>52.5 (29.7)</td>
<td>37.0 (28.3)</td>
<td>59.0 (43.7)</td>
<td>58.9 (37.9)</td>
</tr>
<tr>
<td>Duration in formalin (years):² mean (s.d.)</td>
<td>1.86 (1.46)</td>
<td>2.56 (1.24)</td>
<td>4.40 (2.07)</td>
<td>3.75 (1.49)</td>
</tr>
<tr>
<td>Hospital of origin⁴ (n)</td>
<td>Belfast</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Oxford</td>
<td>5</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Runwell</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Neuroleptic drug prescription¹</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Little</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Much</td>
<td>2</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Duration of illness (years):² mean (s.d.)</td>
<td>N/A</td>
<td></td>
<td>31.20 (8.87)</td>
<td>30.75 (14.44)</td>
</tr>
</tbody>
</table>

ANOVA, analysis of variance; N/A, not applicable.
1. No intergroup differences (by ANOVA, all F₁,₁₂₅ < 0.40, P > 0.531).
2. No intergroup differences (by ANOVA, all F₁,₁₂₅ < 1.12, P > 0.300).
3. Patents longer than controls (by ANOVA, F₁,₁₂₅ = 10.44, P < 0.003); no gender difference or gender × diagnosis interaction (both F₁,₁₂₅ < 1.36, P > 0.255).
4. No intergroup differences (F₁,₁₂₅ = 10.28, d.f. = 6, P = 0.114).
5. No gender difference in patients (F₁,₁₂₅ = 3.85, d.f. = 2, P = 0.146).
6. No gender difference in patients (by ANOVA, F₁,₁₂₅ < 0.005, P = 0.952).

Fig. 1 Hippocampal region CA2/3 with superimposed raster sampling pattern.
OCE can be used to estimate the percentage of observed relative variance, \( (s.d./x)^2 \), of each measure which is accounted for by true inter-individual variance, as opposed to the stereological volume estimate (West & Gundersen, 1990; West, 1999). Ideally, this should be greater than 50%. This was true for all measures of \( V_N \) (all \( \geq 80.2\% \)). The conclusion to be drawn is that the measures are of adequate reliability and accuracy.

**Effects of diagnosis, gender and side**

A bar chart of mean cell volume is given in Fig. 2. The mean cell volumes (standard deviations in parentheses) for the subfields were as follows:

(a) hilus: \( 4.08 \times 10^{-6} \) (0.84 \( \times 10^{-6} \)) for controls and \( 3.82 \times 10^{-6} \) (1.23 \( \times 10^{-6} \)) mm\(^3\) for patients;

(b) CA2/3: \( 3.88 \times 10^{-6} \) (1.09 \( \times 10^{-6} \)) mm\(^3\) for controls and \( 3.45 \times 10^{-6} \) (1.05 \( \times 10^{-6} \)) mm\(^3\) for patients;

(c) CA1: \( 2.54 \times 10^{-6} \) (0.59 \( \times 10^{-6} \)) mm\(^3\) for controls and \( 2.60 \times 10^{-6} \) (0.67 \( \times 10^{-6} \)) mm\(^3\) for patients;

(d) subiculum: \( 2.52 \times 10^{-6} \) (0.57 \( \times 10^{-6} \)) mm\(^3\) for controls and \( 2.25 \times 10^{-6} \) (0.46 \( \times 10^{-6} \)) mm\(^3\) for patients.

There was no significant effect for diagnosis, gender or side for any subfield. Thus, for the hilus, all \( F_{1,24} \leq 1.22, P \geq 0.2021 \); for the CA2/3 subfield, all \( F_{1,24} \leq 3.25, P \geq 0.0842 \); for the CA1 subfield, all \( F_{1,23} \leq 1.35, P \geq 0.2574 \); for the subiculum, all \( F_{1,23} \leq 2.19, P \geq 0.1522 \).

**DISCUSSION**

The main finding in this study is an absence of size change in hippocampal pyramidal neurons in schizophrenia. There have been five earlier studies of this parameter of which we are aware (Christison et al., 1989; West & Gundersen, 1990; Benes et al., 1991, 1998; Arnold et al., 1995; Zaidel et al., 1997; West, 1999); two of them found no change, and three found a decrease in size in schizophrenia. All had comparable numbers of cases of schizophrenia to the number in the present study. Control case numbers were similar to our study in four studies but were larger in one other negative study. All studies used the Nissl stain. Only one previous study in addition to ours looked at both sides of the brain, and only our study sampled the hippocampus throughout its full extent.

We addressed the potential of regional specificity of changes in schizophrenia by dividing the hippocampus into four subfields. We did not further divide our hippocampal subfields into anterior and posterior halves. It is thus possible that changes in one half (anterior or posterior) of a subfield might have been masked or ‘diluted’ by variance in the other half. In a meta-analysis of hippocampal volumes in schizophrenia assessed by MRI it was found that inclusion of the amygdala, abutting on the anterior hippocampus, in the region of interest significantly increased the size of the reduction in volume seen in schizophrenia. The recommendation was made that in future research relative alterations in anterior and posterior hippocampus in schizophrenia should be assessed separately (Nelson et al., 1998). It is also possible that our study might have failed to detect a ‘true’ reduction in cell size in some hippocampal subfields because of the small sample size (type II error).

Decreases in neuronal size have been reported for other regions of the brain in schizophrenia – the dorsolateral prefrontal cortex, anterior cingulate cortex, cerebellar Purkinje cells, substantia nigra and locus caeruleus – but not in the motor cortex or calcarine cortex (reviewed by Harrison, 1999). Further studies will be needed before the primacy of these changes in the disease can be judged.

**ACKNOWLEDGEMENTS**

This work was funded by grants from the UK Medical Research Council and the Wellcome Trust. We thank Drs S. J. Cooper and B. Herron for assistance with clinical assessment and post-mortem brain removal respectively for some of the cases included in this study.

**REFERENCES**


J. R. HIGHLEY, MB DPhil, M. A. WALKER, B. MCDONALD, FRCPATH, Department of Clinical Neurology; T. J. CROW, MB PhD, Department of Psychiatry; M. M. ESIRI, DM FRCPath, Department of Clinical Neurology, University of Oxford, UK

Correspondence: Professor M. M. Esiri, Neuropathology Department, Radcliffe Infirmary, Oxford OX2 6HE, UK. Tel: 01865 224403; fax: 01865 224508; e-mail: margaret.esiri@clneuro.ox.ac.uk

(First received 24 January 2003, final revision 2 June 2003, accepted 4 June 2003)